SMILE for the correction of high myopia: outcomes and epithelial remodelling

Session Details

Session Title: Small Lenticule Extraction I

Session Date/Time: Sunday 15/09/2019 | 08:00-10:00

Paper Time: 09:12

Venue: Free Paper Forum: Podium 1

First Author: : S.Taneri GERMANY

Co Author(s): :    S. Kießler   A. Rost   T. Schultz   H. Dick                    

Abstract Details

Purpose:

Excimer laser-based refractive procedures can have less predictable results when used for correcting high myopia than when used for moderate myopia. Small incision lenticule extraction (SMILE) might overcome this weakness. However, SMILE is only FDA-approved for use in myopic eyes up to - 8 D. We report visual and refractive outcomes and epithelial remodeling after SMILE in highly and moderately myopic eyes.

Setting:

Private practice, Muenster, Germany

Methods:

Observational consecutive case series. Inclusion criteria: attempted myopic spherical correction greater than or equal to 8.0 or -3 to -7.75 D with astigmatism less than or equal to -3.0 D, and corrected distance visual acuity (CDVA) of 1.0 (decimal scale) or better. Epithelial mapping with optical coherence tomography.

Results:

Ninety-two highly myopic and 595 moderately myopic eyes were included. At 3 months, the highly myopic eyes had a mean spherical equivalent refraction of -0.37 +/-0.48D (range: -1.5 to +0.75D) and a mean cylinder of -0.37 +/-0.27 D (range: 0 to -1.5 D). Mean UDVA was 0.93. Mean efficacy index was 0.82. Mean safety index was 1.02. UDVA same or better than CDVA: 62%. Astigmatism was less than or equal to 0.5D in 89% and less than or equal to 1D in 99%. Results in the moderately myopic eyes were comparable. Epithelial remodeling could be demonstrated by averaging the maps.

Conclusions:

We found equally good visual and refractive outcomes after SMILE for the correction of high and of moderate myopia. Improved understanding of epithelial remodeling could potentially further improve results.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented